Vincent Milano Biography and Net Worth

Director of BioCryst Pharmaceuticals

Vincent J. Milano CPA serves as President, Chief Executive Officer, Director of the Company. Prior to joining us, Mr. Milano served as Chairman, President and Chief Executive Officer of ViroPharma Inc., which was acquired by Shire Plc in January 2014, from March 2008 to January 2014, as its Vice President, Chief Financial Officer and Chief Operating Officer from January 2006 to March 2008 and as its Vice President, Chief Financial Officer and Treasurer from April 1996 to December 2005. Mr. Milano also served on the board of directors of ViroPharma from March 2008 to January 2014. Prior to joining ViroPharma, Mr. Milano served in increasingly senior roles, most recently senior manager, at KPMG LLP, an independent registered public accounting firm, from July 1985 to March 1996. Mr. Milano currently serves on the board of directors of Spark Therapeutics, Inc. and Vanda Pharmaceuticals Inc., each a publicly traded company, and VenatoRx Pharmaceuticals, Inc. Mr. Milano holds a Bachelor of Science degree in Accounting from Rider College. He also has corporate governance experience through service on other public company boards.

What is Vincent Milano's net worth?: The estimated net worth of Vincent Milano is at least $372,962.51 as of December 24th, 2018. Mr. Milano owns 55,816 shares of BioCryst Pharmaceuticals stock worth more than $372,963 as of April 7th. This net worth evaluation does not reflect any other assets that Mr. Milano may own. Learn More about Vincent Milano's net worth.
How do I contact Vincent Milano?: The corporate mailing address for Mr. Milano and other BioCryst Pharmaceuticals executives is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. BioCryst Pharmaceuticals can also be reached via phone at (919) 859-1302 and via email at investorrelations@biocryst.com. Learn More on Vincent Milano's contact information.
Has Vincent Milano been buying or selling shares of BioCryst Pharmaceuticals?: Vincent Milano has not been actively trading shares of BioCryst Pharmaceuticals within the last three months. Most recently, on Wednesday, November 24th, Vincent Milano bought 7,500 shares of BioCryst Pharmaceuticals stock. The stock was acquired at an average cost of $12.19 per share, with a total value of $91,425.00. Learn More on Vincent Milano's trading history.
Who are BioCryst Pharmaceuticals' active insiders?: BioCryst Pharmaceuticals' insider roster includes George Abercrombie (Director), Steve Aselage (Director), Yarlagadda Babu (Insider), Alane Barnes (Insider), Anthony Doyle (CFO), Steven Galson (Director), Nancy Hutson (Director), Alan Levin (Director), Amy McKee (Director), Vincent Milano (Director), Machelle Sanders (Director), William Sheridan (Insider), Jon Stonehouse (CEO), and Helen Thackray (Chief Research & Development Officer). Learn More on BioCryst Pharmaceuticals' active insiders.
Are insiders buying or selling shares of BioCryst Pharmaceuticals?: During the last twelve months, BioCryst Pharmaceuticals insiders bought shares 6 times. They purchased a total of 103,601 shares worth more than $596,337.56. During the last twelve months, insiders at the biotechnology company sold shares 2 times. They sold a total of 13,289 shares worth more than $82,486.00. The most recent insider tranaction occured on June, 24th when Director Amy E Mckee sold 8,600 shares worth more than $54,352.00. Insiders at BioCryst Pharmaceuticals own 4.8% of the company. Learn More about insider trades at BioCryst Pharmaceuticals.
Information on this page was last updated on 6/24/2024.

Vincent Milano Insider Trading History at BioCryst Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/24/2021	Buy	7,500	$12.19	$91,425.00

Vincent Milano Buying and Selling Activity at BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Company Overview

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Today's Range

Now: $6.75

$6.43

$7.05

50 Day Range

MA: $8.14

$6.83

$9.39

2 Week Range

Now: $6.75

$4.03

$9.50

Volume

2,935,971 shs

Average Volume

3,216,217 shs

Market Capitalization

$1.41 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.75